Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …

The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …

The clinical use of molecular targeted therapy is rapidly evolving but has primarily focused
on genomic alterations. Transcriptomic analysis offers an opportunity to dissect the …

Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in
melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer …

Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …

The success of checkpoint inhibitors has accelerated the clinical implementation of a vast
mosaic of single agents and combination immunotherapies. However, the lack of clinical …

Checkpoint blockade therapies that reactivate tumour-associated T cells can induce durable
tumour control and result in the long-term survival of patients with advanced cancers …

Immunotherapy has become a key therapeutic strategy in the treatment of many cancers. As
a result, research efforts have been aimed at understanding mechanisms of resistance to …

In recent years, major advances have been made in cancer immunotherapy. This has led to
significant improvement in prognosis of cancer patients, especially in the hematological …

Immunotherapy has become a powerful clinical strategy for treating cancer. The number of
immunotherapy drug approvals has been increasing, with numerous treatments in clinical …